products inhibit the binding of HIV envelope gp120 glycoprotein to CD4 receptors. 18 The limited availability of these natural products makes them attractive targets for total synthesis, but also for the synthesis of simpler analogues with similar properties.
According to this later strategy, Zaesung No et al. synthesized 3,4-dihydropyrimidin-2 (1H) -ones (DHPMs), some of which were selected because of a significant inhibition of HIV-1 replication in vitro, with a good security profile (Fig. 3) . 19 In the present work, we describe the synthesis and pharmacological evaluation of new 3,4-dihydropyrimidin-2(1H)-one derivatives bearing sulfonylurea, urea and thiourea groups, linked to the para or meta positions (compounds 6a-k (series 6) and 7a-j (series 7) respectively) of the 4-phenyl group (Fig. 4) .
To evaluate their vasodilator activity, the target compounds were tested in vitro on rat aortic rings precontracted with 30 mM KCl. The experiments were repeated on rat aortic rings, on the one hand, precontracted with 30 mM KCl in the presence of 10 M glibenclamide and, on the other hand, precontracted with 80 mM KCl, in order to determine their mechanism of action.
Chemistry
The synthetic pathway to 3,4-dihydropyrimidin-2(1H)-ones bearing urea, thiourea or sulfonylurea moieties (6a-k, 7a-j) is described in Scheme 1. Key intermediates (4a-b) were prepared D r a f t 5 anhydrous THF at room temperature. All compounds of series 6 (6a-k) and 7 (7a-j) were recrystallized and characterized by IR, 1 HNMR, 13 C NMR and elemental analysis, prior to be used in pharmacological evaluation.
Results and Discussion

Contractile activity of rat aorta rings
The newly synthesized compounds, 3,4-dihydropyrimidin-2(1H)-ones, bearing urea, thiourea and sulfonylurea moieties (6a-k and 7a-j) were pharmacologically evaluated for their ability to relax isolated rat aorta rings pre-contracted with 30 mM KCl. The VGCCB nifedipine and the potassium channel opener diazoxide were used a reference vasodilators. The results obtained with the target compounds and the reference drugs were expressed as the EC 50 values, which corresponded to the drug concentrations provoking 50% relaxation of the pre-contracted smooth muscle preparation.
The EC 50 values of compounds 6a-k and 7a-j are depicted in Table 1 . The results showed that the sulfonylurea derivatives 6k (para derivative) and 7j (meta derivative) showed very weak vasodilator activity on rat aorta rings (EC 50 > 150 M), compared to the urea and thiourea derivatives. It can be observed in series 6 that all compounds presented a marked vasodilator activity, in particular the thiourea derivatives 6a and 6b, and urea derivatives 6f-i. Indeed, some of the latters were found to be more active than diazoxide, among which compound 6g (EC 50 = 0.983 ± 0.061 M) was the most active (p < 0.05). In terms of structure-activity relationships, groups with a mesomeric electron-donating effect, occupying the para position of phenylureido group, were found to be the most favourable groups for expressing a marked vasodilator activity, as it was the case for 6g and 6h (OCH 3 and Cl respectively). The transfer of the methoxy group (OCH 3 ) to the ortho-position decreased the vasodilator activity by almost twenty-one fold D r a f t 6 compared to that of the para position (6g vs 6f). This trend can also be observed with the series 7 compounds. Indeed, the most active compounds of this series bear a mesomeric electron-donating group (OCH 3 or Cl or F) at the para-position (7f-h) and are all urea derivatives. However, compared to their analogues of series 6 compounds, they were generally found to be relatively less active (7f vs 6g and 7g vs 6h), in particular 6g, which was 17 fold more active than 7f. The inactiveness of sulfonylurea derivatives (6k, 7j) could be due to their weak acidic character, since they have a labile hydrogen atom belonging to the NH group confined between the electronwithdrawing groups, SO 2 and C=O, of the sulfonylurea moiety. This fact means that they could mainly exist as negative ionized species at physiological pH, and that the active form should be neutral. Such a phenomenon has been also observed with other series of compounds possessing urea, thiourea and sulfonylurea moieties, where the latters were also found to be inactive. [21] [22] [23] In order to determine the mechanism of action of the target compounds, the most active one, the urea derivative 6g, was tested again with 30 mM KCl in the presence of 10 M glibenclamide, an ATP-dependent potassium channel blocker, and with 80 mM KCl. Indeed, the vasodilator activity can be provoked either directly by blocking voltage-gated Ca 2+ channels, or indirectly by opening ATP-dependent potassium channels, which hyperpolarizes the membrane cells and causes the blockade of voltage-gated Ca 2+ channels and, consequently, the relaxation process.
Therefore, pure potassium channel openers are able to suppress smooth muscle contractions induced by 30 mM KCl (or less), but not high depolarizing K + concentrations (80 mM). At 80 mM KCl, the potassium equilibrium potential and the cell membrane potential are so close that the hyperpolarization induced by K + channel opening is too weak to close voltage-operated Ca 2+ channels. [24] [25] [26] D r a f t 7 As indicated by table 2 and figure 5, there was no significant change in the vasodilator activity of compound 6g, in the presence of 10 M glibenclamide or 80 mM KCl (p > .05). It means that this compound is probably a voltage-gated calcium channel blocker (nifedipine-like), and certainly not an ATP-dependent potassium channel opener (non diazoxide-like).
Conclusion
In conclusion, we have synthesized and evaluated the vasodilator activity of two series of 3,4-dihydropyrimidin-2(1H)-ones (6 and 7) bearing urea, thiourea and sulfonylurea moieties, at the para (6a-k) or meta (7a-j) positions of the phenyl group at the 4-position of the dihydropyrimidinone ring. Compounds bearing sulfonylurea moieties, belonging to series 6 and 7, namely 6k and 7j, were inactive. The biological results showed that the most interesting compounds are ureas. The most potent vasodilator compounds belong to series 6 such as 6g and 6h, where 6g was found to be twenty fold more active than diazoxide. Further investigations, in the presence of glibenclamide and 80 mM KCl, revealed that compound 6g was a voltage-gated calcium channel blocker like nifedipine. The inactivity of the sulfonylureas, namely 6k and 7j, could be attributed to their partial ionization at the physiological pH, because of their acidic character. Indeed, these compounds possess a labile hydrogen atom on the NH group located between the two electron-attracting C=O and SO 2 groups. This phenomenon was also observed in previous works on other series of compounds, where the sulfonylureas were much less active than urea or thiourea compounds. [22] [23] [24] Therefore, it would be interesting to investigate the Nmethylated sulfonylureas, because they will not be ionized at physiological pH. Further were realized on a Carlo-Erba EA 1108-elemental analyser and were within ± 0.4% of theoretical. All reactions were checked by TLC on silica gel Merck 60 F 254 . Column chromatography was performed on a silica gel Merck 60F 254 using hexane/ ethyl acetate as an eluent system.
General procedure for preparing 4a-b
In a 50 mL flask, the mixture of the appropriate aldehyde (5 mmol), ethyl acetoacetate (5 mmol), urea (7 mmol) and Zn 0.9 Ni 0.1 Al 2 O 4 (20% mass of the aldehyde) in ethanol (10 mL) was stirred under reflux for 4 hours. 20 The product was isolated after filtration of the catalyst on celite and evaporating the solvent. Recrystallization was performed with ethanol to yield pure dihydropyrimidinones 4a-c. The recovered catalyst was dried in an oven at 200 °C for 24 hours, and reused in subsequent reactions. D r a f t 28 Yellow powder (75% 29 Yellow powder (66% 
5-(Ethoxycarbonyl)-4-(4-nitrophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (4a)
5-(Ethoxycarbonyl)-4-(3-nitrophényl)-6-méthyl-3,4-dihydropyrimidin-2(1H)-one (4b)
General procedure for preparing 5a-b
A solution of 4 (10 mmol) in 40 mL of anhydrous THF was hydrogenated over Pd/C (5%) under pressure (10 bars) at 65 °C for 45 min. After filtration on celite, the organic phase was concentrated under vacuum to get crude products, which were purified by silica gel column chromatography using EtOAc/hexane (70/30).
5-(Methylcarbonyl)-4-(4-aminophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (5a) 28
White powder (89% 29 White powder (93% 
5-(Ethoxycarbonyl)-4-(3-aminophenyl)-6-méthyl-3,4-dihydropyrimidin-2(1H)-one (5b)
General procedure for preparing 6a-k and 7a-j
The appropriate aryliso(thio)cyanat or sulfonylisocyanate (2.2 mmol) was added to a solution of 5 (2 mmol) in anhydrous THF (5 mL). The reaction mixture was stirred at room temperature until completion of the reaction monitored by TLC. The solvent was removed under vacuum and the resulting precipitate was collected by filtration, washed with diethyl ether, and dried. The product was recrystallized with acetone/water. Ethyl 6-methyl-4-(4-{[(4-chlorophenyl)carbamothioyl]amino}phenyl)-6-methyl-2-oxo-1,2,3,4 {[(2-methoxylphenyl)carbamoyl]amino}phenyl)-6-methyl-2-oxo-1,2,3,4 
Ethyl 4-(4-
Ethyl 4-(4-{[(4-methoxylphenyl)carbamoyl]amino}phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (6g)
White powder (95% 
Ethyl 4-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (6i)
White powder (68% {[(2-methoxyphenyl)carbamoyl]amino}phenyl)-6-methyl-2-oxo-1,2,3 Hz), 4.00 (q,2H, CH 2 , J = 7.25Hz), 2.24 (s, 3H, CH 3 ), 1.13 (t, 3H, CH 3 , J=7.25 Hz). 13 
Ethyl 4-(3-
Statistical evaluation
The statistical significance of differences between mean data was assessed by using the ANOVA.
The biological results were considered statistically different when p < .05. glibenclamide;■80 mMKCl. Data are expressed as mean ± SEM of (n) rat aorta rings. 
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